Cytosorbents (NASDAQ:CTSO) Receives “Neutral” Rating from HC Wainwright

HC Wainwright restated their neutral rating on shares of Cytosorbents (NASDAQ:CTSO) in a report published on Tuesday, Benzinga reports. HC Wainwright currently has a $1.00 price target on the medical research company’s stock.

Separately, StockNews.com started coverage on shares of Cytosorbents in a research report on Thursday, May 2nd. They issued a hold rating on the stock.

Cytosorbents Price Performance

Shares of NASDAQ CTSO opened at $0.93 on Tuesday. The company has a current ratio of 1.77, a quick ratio of 1.51 and a debt-to-equity ratio of 0.11. The stock has a fifty day simple moving average of $0.91 and a two-hundred day simple moving average of $1.12. Cytosorbents has a 1-year low of $0.78 and a 1-year high of $4.29. The firm has a market cap of $50.63 million, a price-to-earnings ratio of -1.46 and a beta of 0.62.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Thursday, March 14th. The medical research company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.02. Cytosorbents had a negative return on equity of 120.24% and a negative net margin of 78.43%. The company had revenue of $8.67 million during the quarter, compared to the consensus estimate of $9.29 million. Analysts anticipate that Cytosorbents will post -0.36 earnings per share for the current year.

Institutional Trading of Cytosorbents

A number of hedge funds and other institutional investors have recently made changes to their positions in CTSO. Key Client Fiduciary Advisors LLC grew its holdings in Cytosorbents by 188.0% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock valued at $33,000 after buying an additional 22,557 shares in the last quarter. Avenir Corp grew its stake in Cytosorbents by 12.3% during the fourth quarter. Avenir Corp now owns 3,051,402 shares of the medical research company’s stock valued at $3,387,000 after acquiring an additional 334,005 shares in the last quarter. Neuberger Berman Group LLC increased its holdings in Cytosorbents by 19.9% during the 4th quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock worth $1,997,000 after acquiring an additional 299,103 shares during the period. Skylands Capital LLC lifted its stake in Cytosorbents by 10.5% in the 4th quarter. Skylands Capital LLC now owns 3,254,213 shares of the medical research company’s stock worth $3,612,000 after purchasing an additional 309,543 shares in the last quarter. Finally, Sargent Investment Group LLC boosted its holdings in Cytosorbents by 4.1% in the 4th quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock valued at $1,453,000 after purchasing an additional 51,699 shares during the period. 32.87% of the stock is currently owned by institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.